Trial · NCT06120881
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Acceptability of Higher Metformin Dose measured with the Acceptability of Intervention Measure (AIM) | Measured at 3 months | The perception that a higher dose of Metformin is agreeable or satisfactory measured with the 4-item Acceptability of Intervention Measure (AIM). A 4-item measure of perceived intervention acceptability. Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). Score is calculated mean. The greater the score, the better the acceptability. |
| Primary | Feasibility of Higher Metformin Dose measured with the Feasibility of Intervention Measure (FIM) | Measured at 3 months | The extent to which a higher dose Metformin study can be successfully carried out measured with 4-item Feasibility of Intervention Measure (FIM). A 4-item instrument to assess perceived intervention feasibility. Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). Score is calculated mean. The greater the score, the better the feasibility. |
| Secondary | Glycemic Change | Baseline (0) to 3 months | Change in serum HbA1C at 3 months adjusted for the baseline value youth with T2D on higher dose of metformin compared to standard dose |
| Secondary | Time in target glucose range | Baseline (0) to 3 months | Time spent in target glucose range of 70 to 180 mg/dL |
| Secondary | Time above high glucose range | Baseline (0) to 3 months | Percent of readings and time \>250 mg/dL |
| Secondary | Time above glucose range | Baseline (0) to 3 months | Percent of readings and time 181-250 mg/dL |
| Secondary | Time in glucose range | Baseline (0) to 3 months | Percent of readings and time 70-180 mg/dL |
| Secondary | Time below glucose range | Baseline (0) to 3 months | Percent of readings and time 54-69 mg/dL |
| Secondary | Time below low glucose range | Baseline (0) to 3 months | Percent of readings and time \<54 mg/dl |
| Secondary | Glucose management indicator | Baseline (0) to 3 months | Continuous glucose monitoring (CGM) metric that indicates average blood glucose. Glucose Management Indicator (GMI) approximates the laboratory A1C level expected based on average glucose measured using CGM values. Average glucose is derived from 14 or more days of CGM readings. |
| Secondary | Co-efficient of variation of glucose | Baseline (0) to 3 months | CGM metric that measures variability in CGM values |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06120881/registered